Video Insights
Advertisement
Dr. Brian Shuch gives a preview of Urology on the Beach 2025, including his session on molecular imaging agents.
Dr. Shuch shares the key points from his presentation on advancements in molecular imaging for RCC from SUO 2024.
Dr. Daneshmand discusses the impressive complete response rate and durability of TAR-200 monotherapy for NMIBC.
In the PENELOPE study, TAR-200 showed greater tissue penetration of gemcitabine compared to standard intravesical therapy.
Dr. Christopher Cutie shares his thoughts on the potential of TAR-200 to redefine care for BCG-unresponsive, HR NMIBC.
Dr. Christopher Cutie describes the innovative TAR-200 system and its role in providing sustained intravesical drug delivery.
Drs. Saji and Lebastchi provide an in-depth overview of focal therapy for prostate cancer, including HIFU and IRE therapies.
Dr. Barragán-Carrillo discusses the current state of RCC treatment, including ICIs, TKIs, and dual ICI regimens.
Dr. Li provides background and insights on the implications of his study on oncolytic immunotherapy with nivolumab for MIBC.
Dr. Brown shares highlights from the CME program at LUPGA 2024, including new trends in bladder, kidney, and prostate cancer.
Dr. Jayram breaks down important topics in kidney cancer from LUGPA 2024, including adjuvant pembrolizumab post-nephrectomy.
Dr. Jayram provides insights into the BCG-unresponsive and BCG-naive bladder cancer space at the LUGPA 2024 Annual Meeting.
Dr. Hafron breaks down the most important updates in upper tract urothelial carcinoma from the LUGPA 2024 Annual Meeting.
Ana Kiess, MD, PhD, of Johns Hopkins Medicine, reviews the phase II RAVENS trial on radium-223 with SABR versus SABR alone.
Dr. Sartor offers insight on the efficacy of 177Lu-PSMA-617 in prolonging progression-free survival rates.
Dr. Daneshmand reviews data from ENVISION on mytomycin for patients with intermediate-risk bladder cancer.
Dr. Daneshmand talks about key studies and exciting developments in bladder cancer from the LUGPA 2024 Annual Meeting.
Drs. Michael Whalen and Vincent Xu discuss potential alternative treatments for patients who are ineligible for chemotherapy.
Drs. Michael Whalen and Vincent Xu discuss their recent analysis of neoadjuvant chemotherapy utilization for UTUC.
In part six of this roundtable series, the panelists finish their discussion by reviewing immunotherapy in prostate cancer.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.